



VICTORIA UNIVERSITY
MELBOURNE AUSTRALIA

Homology modeling and molecular dynamics simulations of MUC1-9/H-2Kb complex suggest novel binding interactions

This is the Accepted version of the following publication

Stavrakoudis, A, Tsoulos, IG, Uray, K, Hudecz, F and Apostolopoulos, Vasso (2011) Homology modeling and molecular dynamics simulations of MUC1-9/H-2Kb complex suggest novel binding interactions. *Journal of Molecular Modeling*, 17 (7). 1817 - 1829. ISSN 1610-2940

The publisher's official version can be found at
<https://link.springer.com/article/10.1007/s00894-010-0884-4>
Note that access to this version may require subscription.

Downloaded from VU Research Repository <https://vuir.vu.edu.au/33937/>

Homology modeling and molecular dynamics simulations of MUC1-9/H-2K^b complex suggest novel binding interactions

Athanassios Stavrakoudis,¹ Ioannis G. Tsoulos,² Katalin Uray,³
Ferenc Hudecz^{3,4} and Vasso Apostolopoulos⁵

¹ Department of Economics, University of Ioannina, Ioannina, Greece

² Department of Communications, Informatics and Management, Technological Educational Institute of Epirus, Arta, Greece

³ Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Budapest, Hungary

⁴ Institute of Chemistry, Eötvös Loránd University, Budapest, Hungary

⁵ Immunology and Vaccine Laboratory, Centre for Immunology, The Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Australia

Correspondence:

Athanassios Stavrakoudis, Department of Economics, University of Ioannina, GR-451 10, Ioannina, Greece, tel: +30 265 100 5935, fax: +30 265 100 5092, email: astavrak@cc.uoi.gr, web: <http://stavrakoudis.econ.uoi.gr>

Vasso Apostolopoulos, Immunology and Vaccine Laboratory, Centre for Immunology, The Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Australia tel: +61 3928 22111, fax: +61 3928 22100, email: vasso@burnet.edu.au

1 Abstract

2 Human MUC1 is over-expressed on human adenocarcinomas and has been used as a
3 target for immunotherapy studies. The 9-mer MUC1-9 peptide has been identified
4 as one of the peptides which binds to murine MHC class I H-2K^b. The structure
5 of MUC1-9 in complex with H-2K^b has been modeled and simulated with classical
6 molecular dynamics, based on the x-ray structure of the SEV9 peptide/H-2K^b com-
7 plex. Two independent trajectories with the solvated complex (10 ns in length) were
8 produced. Approximately 12 hydrogen bonds were identified during both trajec-
9 ries to contribute to peptide/MHC complexation, as well as 1-2 water mediated
10 hydrogen bonds. Stability of complex was also confirmed by buried surface area
11 analysis, although the corresponding values were about 20% lower than those of the
12 original x-ray structure. Interestingly, a bulged conformation of the peptide's cen-
13 tral region, partially characterized as a β -turn, was found exposed from the binding
14 groove. In addition, P1 and P9 residues remained bound in the A and F binding
15 pockets, even though there was suggestion that P9 was more flexible. The complex
16 lacked the numerous water mediated hydrogen bonds that were present in the refer-
17 ence peptide x-ray structure. Moreover, local displacements of residues Asp4, Thr5
18 and Pro9 resulted in loss of some key interactions with the MHC molecule. This
19 might explain the reduced affinity of the MUC1-9 peptide, relatively to SEV9, for
20 the MHC class I H-2K^b.

21 **Keywords:** Class I MHC; H-2K^b; homology modeling; molecular dynamics; MUC1;
22 tumor

1 Introduction

Major histocompatibility complex (MHC) proteins bind small peptide fragments derived from pathogenic proteins and form peptide/MHC (pMHC) complexes (Raghavan et al., 2008). MHC proteins are divided into two classes: class I (MHC-I) and class II (MHC-II). The MHC-I consists of a polymorphic transmembrane heavy chain and β 2-microglobulin, which are non-covalently associated (Zhang et al., 1998). The proteolysis of intracellular proteins by the proteasome produces the majority of peptides suitable for MHC-I binding. In most cases, peptides of 8-10 residues in length are found in the binding groove of MHC-I.

After the first crystal structures of pMHC complexes were available, (Bjorkman et al., 1987; Fremont et al., 1992; Matsamura et al., 1992) it was suggested that peptides bound to MHC-1 with a canonical extended structure. MHC class I residues that form the binding groove are responsible for the specificity of the peptide selection. Six (out of 8-10) residues of the peptide sequence are accommodated within the A-F binding pockets of the MHC-I protein (Saper et al., 1991). Residues that do not participate directly in binding are believed to interact with the TCR.

Human mucin, MUC1, is a membrane-bound glycoprotein, expressed on the surface of epithelial cells. It is often overproduced and/or underglycosylated in adenocarcinomas (breast, ovary, colon, lung, kidney, etc) and is present in the serum of cancer patients. MUC1 is immunogenic in mice and in humans, with both humoral and cellular immune responses being induced by MUC1-based vaccine constructs (Tang et al., 2008b,a). MUC1 mucin partly consists of a variable number of tandem repeats region of the consensus sequence 1 PDTRPAPGSTAPPAHGVTSA 20 which is repeated 40-80 times (Gendler et al., 1988). The majority of anti-MUC1 antibodies recognize sequences within the SA 1 PDTRPAP 7 region (Price et al., 1991; Xing et al., 1991, 1992; Burchell et al., 1989). The SAPDTRPAP (MUC1-9) 9-mer peptide was also found to be presented by MHC-1 H-2K b and to be immunogenic (Apostolopoulos et al., 1997). MUC1-9 binds with low affinity to H-2K b (Apostolopoulos

51 et al., 1997) via a noncanonical mode and it was suggested that the C-terminus of
52 the peptide looped out of the peptide binding groove (Apostolopoulos et al., 1998;
53 Apostolopoulos and Lazoura, 2004).

54 Computer simulation of molecular dynamics is a well established method for
55 studying several aspects of biomolecular structure and function (Hansson et al.,
56 2002; Karplus, 2003; Aksimentiev et al., 2008; Tantar et al., 2008). In recent years
57 such computational approaches have been increasingly incorporated in drug design
58 (Galeazzi, 2009), in immunological research (Morikis and Lambris, 2004; Mallik and
59 Morikis, 2006; Stavrakoudis, 2010) and also to peptide/MHC complexes (Omasits
60 et al., 2008; Knapp et al., 2009). Moreover, biomolecular modeling can complement
61 experimental studies (van Gunsteren et al., 2008) and can elucidate dynamics of
62 immunological synapse (Wan et al., 2008), allows to study the dynamics of a peptide
63 bound to antibody (Tatsis et al., 2009; Stavrakoudis, 2009b), could be used to model
64 disulphide peptide complexed proteins (i.e. C8 γ (Stavrakoudis, 2009a)) or even more
65 excitingly to help in clinical decision making (Sadiq et al., 2008).

66 Modeling of the MUC1-9 peptide with both murine and human MHC class I,
67 H-2K^b and HLA-A2 respectively have been previously performed (Apostolopoulos
68 et al., 1998), based on a simulated annealing protocol and high temperature molec-
69 ular dynamics (Chelvanayagam et al., 1996). That work was a considerable progress
70 in our knowledge of peptide/MHC interactions in the MUC1-9 case and provided a
71 possible structural explanation of the antibody binding of MUC1 peptides presented
72 by the MHC molecules. However, modern progress in computational biophysics, ac-
73 companied with the big enhancement of available computer power, can be utilized to
74 further improve the computer-generated model of the MUC1-9 peptide complexed
75 the the MHC class I H-2K^b.

76 Here, we present a homology modeling and molecular dynamics approach of
77 MUC1-9 (SAPDTRPAP) in complex with MHC class I H-2K^b. Since the initial
78 conformation was modeled rather than taken from an x-ray structure, we chose

79 to perform two indepent simulation runs, to obtain more robust results. Long-
80 run dynamics, inclusion of the whole MHC molecule and explicit representation of
81 solvent have been utilized in order to more accurate picture the MUC1-9 structure
82 and interactions with the MHC molecule. Such approach has been suggested to
83 give more reliable results in MD investigations (van Gunsteren et al., 2008; Omasits
84 et al., 2008). Our results suggest that this was a beneficial approach in the current
85 study, and has given insights into the peptide binding mode of the MUC1-9.

86 2 Methods

87 Initial coordinates for the SEV9/MHC complex were downloaded from Protein Data
88 Bank (Berman et al., 2002), access code: 1kpv.

89 The original peptide from sendai-virus, FAPGNYPAL was mutated to SAPDTR-
90 PAP, whilst MHC molecule remained untouched. The SEV9 peptide was selected
91 from other candiditates due to its homology with the MUC1-9 peptide. Pro residue
92 homology in positions P3 and P7 was also crucial for selection. Since the backbone
93 dihedral angle ϕ of Pro residue is restrained, it is preferable to choose a peptide
94 that has the same residue in these positions. Ideally, it would be perfect to also
95 have alignment for position P9, however there was no such option. Topology and
96 force field parameters for all atoms were assigned from the CHARMM22-CMAP
97 parameter set (Mackerell et al., 2004; MacKerell et al., 2004). It has been noted
98 that addition of cross terms with CMAP potential improves the system parametriza-
99 tion and helps to avoid undesired backbone helical transitions (Buck et al., 2006;
100 Stavrakoudis, 2008).

101 Hydrogen atoms were added with the VMD program (Humphrey et al., 1996)
102 and its autopsf utility. Protonation status of Histidine side chains were determined
103 with the REDUCE program (Word et al., 1999). The peptide/MHC complex was
104 centered in a rectagular box with dimensions $95.7 \times 88.3 \times 102.9 \text{Å}^3$. The box was filled

105 with TIP3P water molecules and neutralized with the addition of 26 Na⁺ and 20
106 Cl⁻ ions respectively, to approximate a 0.1 mM ion concentration. Crystallographic
107 water molecules (345) were also included in the model. The final system contained
108 24429 water molecules. Total number of atoms of the entire system were 80598.

109 Non-bonded van der Waals interactions were gradually turned off at a distance
110 between 12 and 14 Å (Yonetani, 2006). Long range electrostatics were calculated
111 with the PME method (Darden et al., 1993). Non-bonded forces and PME elec-
112 trostatics were computed every second step. Pair list was updated every 10 steps.
113 Bonds to hydrogen atoms were constrained with the SHAKE method allowing a 2 fs
114 time step for integration. The system was initially subjected to energy minimization
115 with 5 000 steps. The temperature of the system was then gradually increased to 310
116 K, with Langevin dynamics using the NVT ensemble, during a period of 3 000 steps,
117 by stepwise reassignment of velocities every 500 steps. The simulation was continued
118 at 310 K for 100 000 steps (200 ps). During minimization and equilibration phases,
119 protein backbone atoms (N, C^α, C', O) and oxygen atoms of crystallographic waters
120 were restrained to their initial positions with a force constant of 50 kcalmol⁻¹Å⁻².
121 The system was equilibrated for further 200 ps with the force constant reduced to
122 5 kcalmol⁻¹Å⁻². Finally, 400 ps of NVT simulation at 310 K was performed with
123 total elimination of the positional restraints. The simulation was passed to the
124 productive phase, by applying constant pressure with the Langevin piston method
125 (Feller et al., 1995). Velocities were re-initialized and two independent trajectories
126 were produced (trA and trB). Pressure was maintained at 1 atm and temperature
127 at 310 K. Results are based to a period of 10 ns of this isothermal-isobaric (NPT)
128 runs. Snapshots were saved to disk at 1 ps interval for structural analysis.

129 The initial structure of the SEV9/MHC complex (PDB code 1kpj) were also
130 simulated under identical conditions for comparative analysis (tr0 trajectory).

131 Trajectory analysis was performed with Eucb (Tsoulos and Stavrakoudis, 2009)
132 and Carma (Glykos, 2006) software packages. Secondary structure analysis was

133 performed with STRIDE (Frishman and Argos, 1995). Circular data statistics (di-
134 hedral angles, etc) were calculated with appropriate corrections (Agostinelli, 2009).
135 Structural figures were prepared with PyMOL (www.pymol.org).

136 2.1 Buried surface area calculation

137 Calculation of buried surface area (BSA) was performed with the NACCESS pro-
138 gram (<http://www.bioinf.manchester.ac.uk/naccess/>), based on the formula:

$$BSA = S_p + S_a - S_c \quad (1)$$

139 thus as the difference of the surface accessible area of the complex (S_c) from the
140 sum of the of surface accessible areas of the peptide (S_p) and MHC molecule (S_a)
141 respectively.

142 β -turn classifications were based on geometrical characteristics of the backbone
143 conformation (Hutchinson and Thornton, 1994). Initially, a β -turn was accepted if
144 $d(C_i^\alpha - C_{i+3}^\alpha) \leq 7\text{\AA}$ and $|\alpha(C_i^\alpha - C_{i+1}^\alpha - C_{i+2}^\alpha - C_{i+3}^\alpha)| < 90^\circ$, where d is the distance
145 and α is the dihedral angle between the corresponding atoms. Further classification
146 of the β -turn was based on hydrogen bond patterns and backbone dihedral values
147 of the $i + 1$ and $i + 2$ residues.

148 In order to indentify isolated (from the bulk) water molecules in the peptide/MHC
149 interface the instantaneous water coordination number (N_c) approach (Petrone and
150 Garcia, 2004). This method counts the water oxygen atoms within a range (typically
151 3.5\AA) of any water oxygen atom, which is actually the first hydration shell. The N_c
152 can be found between 0 and 15, depending on the local structure of water. In the
153 bulk water this number is always greater than 3, while in the protein interior is 0 to
154 2. This implies that a water molecule has no other water neighbours and it is inside
155 the protein interior. The N_c is measured for all the MD trajectory and isolated
156 water molecules are indentified if the N_c value is small for a prolonged period of

157 time. In the current study, a search of water molecule with $N_c \leq 1$ for at least 70%
158 of the MD time has been performed.

159 **2.2 MM-PBSA calculation of $\Delta G_{binding}$**

160 The binding free energy of the association of two molecules (A+B→AB) can be
161 estimated, according to the MM-PBSA approach (Kollman et al., 2000; Wan et al.,
162 2005), as:

$$\Delta G_{binding} = G^{AB} - G^A - G^B, \quad (2)$$

163 where:

$$\Delta G^i = \langle E_{MM} \rangle + \langle G_{solv} \rangle - TS. \quad (3)$$

164 In the above equations, $\langle . \rangle$ denotes average value for a set of snapshots along a
165 molecular dynamics trajectory, while E_{MM} is the molecular mechanics energy of the
166 i^{th} molecule in the gas phase, namely the sum of internal bonded energy (comprising
167 bond, angle and dihedral terms), van der Waals and electrostatic interactions. G_{solv}
168 is the solvation free energy of the i^{th} molecule. This term can be estimated as the
169 sum of the electrostatic solvation free energy calculated by the Poisson–Boltzmann
170 equation and the non-polar solvation free energy calculated from the SASA.

171 Hence, the binding free energy is:

$$\Delta G^i = \langle \Delta E_{MM} \rangle + \langle \Delta G_{solv} \rangle - TS. \quad (4)$$

172 The average properties can be computed directly from the MD trajectory snap-
173 shots. In the current study, the last 5 ns were used, assuming that equilibrium was
174 reached after the first 5 ns of the simulation. 5000 structures were utilized for the
175 SASA and E_{MM} calculations, while 50 structures (one every 100 frames) were used
176 for the calculation of the G_{solv}^{elec} with the APBS (Baker et al., 2001; Dolinsky et al.,
177 2004) software.

178 **3 Results and Discussion**

179 **3.1 RMSF and RMSD analysis**

180 Root mean square fluctuations (RMSF) of the C $^{\alpha}$ atoms of the MHC and peptide
181 chains, as well as the time evolution of the root mean square deviation (RMSD) of
182 the backbone atoms (N, C $^{\alpha}$, C $^{\prime}$) of the MHC and peptide chains, during both MD
183 trajectories, trA and trB respectively, are shown in Figure 1.

184 In both trA and trB cases, RMSF profiles of chains A and B from the MHC
185 molecule were almost identical, which indicates the robustness of the study. RMSF
186 values were between 0.5 and 2.0 Å, which is quite common in similar MD studies
187 of protein complexes around equilibrium. Similarly, RMSD time series were also
188 very similar for chain A and B, with only a small exception of the trA trajectory:
189 RMSD values escaped from stationarity around 4ns in trA, and a small peak of
190 RMSD 0.28 Å was observed. In general, both trajectories were quite stable, Fig-
191 ure 1. Time series of RMSD fluctuated around 1.5–2.0 Å for chain A and around
192 1.0 Å for chain B. If we take into consideration the simulation temperature (310 K)
193 these values are considered small, indicating the stability of the complex. Moreover,
194 there is strong evidence that the MHC molecule did not undertake significant con-
195 formational changes upon mutation of the peptide residues (Fremont et al., 1992;
196 Matsamura et al., 1992). This is in accordance with other X-ray studies of the H-
197 2K b MHC class-I molecule with different nonamer peptides in the binding groove.
198 These observations corroborate our hypothesis that homology modeling coupled
199 with molecular dynamics simulations produces a reliable model of the MUC1-9/H-
200 2K b complex.

201 Peptide’s RMSF values of C $^{\alpha}$ atoms showed an interesting differentiation between
202 trA and trB trajectories. While values of 0.5-1.0 Å were recorded for residues 1-7
203 in both cases, trA trajectory showed increased values of 1.5 and 2.0 Å for residues
204 8 and 9 respectively. In trB trajectory, RMSF remained close to 1.0 Å for all

205 residues. Values in the order of 2.0 Å are still considered relatively small, however,
206 the differentiation is notable. Since this fact was observed in only one of the two
207 trajectories, it could be considered as a relative random effect of the simulation.
208 On the other hand, it definitely indicates that the peptide binding to the MHC
209 groove is not so tight at the C-terminal region, as previously has been suggested
210 (Apostolopoulos et al., 1998; Apostolopoulos and Lazoura, 2004).

211 Peptide's RMSD time series of backbone atoms were very similar in both cases.
212 RMSD values ranged between 0.99 and 2.1 Å and averaged at 1.46 (0.16) Å for
213 trA, whilst the RMSD values ranged between 1.04 and 1.69 Å and averaged at 1.36
214 (0.09) for trB case. There is only a minor difference between these two profiles:
215 trB trajectory showed slightly smaller values with smaller standard deviation of the
216 time series. This is possibly due to increased fluctuation at the C-terminal end in
217 trA. However, as it was previously noted for chains A and B of the MHC molecule,
218 RMSD profiles of the peptide corroborate the stability of the trajectories and the
219 validity of the proposed model.

220 3.2 Peptide backbone dynamics

221 Backbone conformations play an important role in peptide/MHC binding (Barinaga,
222 1992; Matsamura et al., 1992). Here we present a detailed analysis of the peptide's
223 backbone conformation.

224 Figure 2 displays the distribution (Ramachandran map) of the backbone dihedral
225 angles ϕ, ψ of peptide residues in the region 2-8. It is evident that, for most of the
226 residues, the backbone dihedrals show very similar distributions in the trA and trB
227 trajectories. The only exception comes from the **Ala8** residue. As it has been noted,
228 the C-terminal residues showed increased mobility (higher RMSF values), and this
229 is very well reflected in the distribution of its backbone dihedral angles.

230 The initial values of -61° and 150° of ϕ, ψ angles of **Ala2** were well conserved
231 during both MD trajectories. Percentage of dihedral angles from both trA and trB

232 trajectories within 30° of the initial values were found 98% and 80% for ϕ, ψ angles
233 respectively.

234 **Pro3**'s backbone ϕ, ψ dihedral angles was -60° and 146° respectively in the initial
235 structure. As it was expected, the fluctuation of ϕ was found rather small, and over
236 60% of the frames were found within 15° of the initial value ($>99\%$ if 30° bin is
237 taken into consideration). Backbone ψ angle also showed minimal fluctuation and
238 more than 80% of the frames in both trA and trB trajectories were found within
239 30° of the initial value.

240 **Asp4**'s backbone ϕ, ψ dihedral angles were -120° and 153° respectively in the
241 initial structure. Contrary to the **Pro3** case, **Asp4** residue experienced a significant
242 move to its backbone ϕ dihedral angle. Time series of this angle fluctuated between
243 -30° and -122° and averaged at $-69^\circ(11^\circ)$. Only 35% of the trA frames and 55% of
244 the trB frames remained within 30° of the initial value. Similarly, backbone ψ angle
245 averaged at $-35^\circ(12^\circ)$. Thus **Asp4** residue showed (in total) an approximately 100°
246 move in backbone dihedral angles. It could be considered that **Asp4** represents a
247 first differentiation between the crystal structure of the reference peptide and the
248 MUC1-9 peptide studied here.

249 **Thr5**'s backbone ϕ, ψ dihedral angles were 74° and 48° respectively in the initial
250 structure of the SEV9 peptide. A positive ϕ angle, although abnormal in other cases,
251 is not uncommon in peptide's conformation of other peptide/MHC complexes. For
252 example ϕ angle of residue Ser5 was found to be 60° in SRDHSRTPM (YEA9)
253 peptide (Apostolopoulos et al., 2002). During both trA and trB trajectories, the
254 sign of backbone ϕ dihedral angle of residue **Thr5** changed quickly and the residue
255 adopted backbone ϕ angles close to -150° (Figure 2). Time series of **Thr5**'s ϕ angle
256 averaged at $-151^\circ(22^\circ)$ in both trA and trB trajectories. Negative values of ϕ at
257 position 5 have also been observed in other crystal structures of peptide/MHC H-
258 $2K^b$ complexes. For example, in the SSYRRPVGI peptide from influenza A virus,
259 the ϕ angle of Arg5 was found to be -67° (PDB access code 1wbz) (Meijers et al.,

260 2005). The identical results obtained in both trajectories underline the robustness
261 of the found values for **Thr5**'s ϕ angle. Backbone dihedral ψ of **Thr5** averaged at
262 $162^\circ(65^\circ)$ and $160^\circ(49^\circ)$ in trA and trB trajectories respectively. Average values are
263 approximately 115° different from the initial value.

264 **Arg6**'s backbone ϕ, ψ dihedral angles was -59° and 107° respectively in the initial
265 structure. Similarly to **Thr5**, backbone dihedral angles were altered during MD
266 trajectories. Average values of ϕ angle were found to be $-129^\circ(14^\circ)$ and $-128^\circ(13^\circ)$
267 in trA and trB trajectories respectively. Average values of ψ angle were found to
268 be $153^\circ(17^\circ)$ and $151^\circ(12^\circ)$ in trA and trB trajectories respectively. Only 47% of
269 trajectories frames in trA and 30% in the trB retained backbone dihedrals within
270 30° of the initial values.

271 **Pro7**'s backbone ϕ, ψ dihedral angles was -57° and 144° respectively in the initial
272 structure. Average values of ϕ angle were found to be $-49^\circ(13^\circ)$ and $-53^\circ(13^\circ)$ in
273 trA and trB trajectories respectively. Average values of ψ angle were found to
274 be $138^\circ(21^\circ)$ and $143^\circ(19^\circ)$ in trA and trB trajectories respectively. After three
275 continuous residues that escaped the initial conformation, **Pro7** retained mostly its
276 initial structure.

277 **Ala8**'s backbone ϕ, ψ dihedral angles were -65° and 145° respectively in the
278 initial structure. **Ala8**'s backbone ϕ angle averaged at $-119^\circ(28^\circ)$ and $-118^\circ(19^\circ)$
279 during trA and trB MD trajectories respectively. As it is indicated by the higher
280 standard deviation value, and it is also seen in Figure 2, values of ϕ backbone
281 dihedral showed significant more dispersion during trA trajectory than in trB. This
282 is in accordance with the higher RMSF value observed for **Ala8** in the trA trajectory.
283 Backbone dihedral angle ψ was found to be similar to its initial values. Average
284 values of ψ angle were found to be $140^\circ(21^\circ)$ and $130^\circ(15^\circ)$ in trA and trB trajectories
285 respectively.

286 **Pro9**'s ϕ dihedral angle remained close to -70° (as it is expected from the pro-
287 line's cyclic structure). The original (from the x-ray structure, Leu9) angle was

288 -70.9°. Thus, there was no significant backbone difference in this part of the pep-
289 tide.

290 Hairpin and β -turn structures in peptides bound to MHC molecules have been
291 identified in case of MHC class II molecules (Zavala-Ruiz et al., 2004). However,
292 this happens to the peptide's region that is outside of the binding group. In the
293 current study, we have identified a very interesting case of β -turn in the central
294 region of the peptide, covering residues **Pro3** to **Arg6**. This sequence has been
295 found in β -turn conformation for 50 and 77% of the simulation time, in the trA
296 and trB trajectories respectively. We did not recorded any intra-peptide hydrogen
297 bond stabilizing this β -turn. Table 1 lists the values of backbone dihedral angles as
298 calculated for the central residues of the β -turn, **Asp4** and **Thr5** respectively. Both
299 trA and trB trajectories showed very close values of backbone ϕ and ψ dihedrals.
300 These values differ from the initial values found in the crystal structure of the SEV9
301 peptide. However, the common finding from the two independent trajectories (trA
302 and trB) corroborate the suggestion that a β -turn around the **Asp4-Thr5** region
303 exists, at least partially.

304 **3.3 Interactions between the peptide and the MHC**

305 The binding mode of nonamer peptides with the H-2K^b MHC class I molecule has
306 been investigated in the past. There are numerous studies in the literature (Mat-
307 samura et al., 1992; Fremont et al., 1992; Apostolopoulos et al., 2002; Meijers et al.,
308 2005; D. H. Fremont and E. A. Stura and M. Matsumura and P. A. Peterson and
309 I. A. Wilson, 1995) addressing the principles of peptide anchoring to MHC's bind-
310 ing groove. It is generally assumed that H-2K^b has six binding pockets, A to F,
311 that accomodate residues P1,P2,P3,P6,P7 and P9 of nonamer peptides (Matsamura
312 et al., 1992; Saper et al., 1991). Residues P4 and P5 do not make direct contacts
313 with the MHC molecule and protrude towards the solvent, hence their side chains
314 are available for interaction with the TCR. The charge groups of N- and C-terminal

315 residues make strong interactions with the MHC binding clefts (pockets A and F
316 respectively).

317 A general view of the peptide/MHC binding motif is shown in Figure 3, whilst
318 the peptide's orientation inside the MHC's binding is depicted at Figure 4.

319 Peptide's **Ser1** (P1) was found to form two stable hydrogen bonds with the
320 MHC molecule. Its backbone atoms N and O were found in hydrogen bond state
321 with side chains of Glu63A and Tyr159A respectively. These hydrogen bonds were
322 conserved, in both trA and trB trajectories, for approximately 91 to 95% of the
323 simulation time (Table 2). The distance between Ser1:N and Glu63A side chain
324 oxygen atoms, in the initial structure, were found 4.6 and 5.8 Å for O^{ε1} and O^{ε2}
325 respectively, which indicates that this strong (charged) hydrogen bond between the
326 N-terminal group of the peptide and the side chain of Glu63A was formed during
327 the modeling process and was not present in the initial structure. Indeed, Glu63A's
328 side chain (atom O^{ε1}) actually was to form a hydrogen bond with Ala2:N atom, in
329 the structure of the original peptide (Matsamura et al., 1992). The hydrogen bond
330 between Ser1:O and Tyr159A:O^η, on the other hand, was well formed in the initial
331 structure (distance 2.67 Å) and very well conserved in both MD trajectories (Table
332 2). Another hydrogen bond interaction between Ser1 and the MHC molecule was
333 present between the side chains of Ser1 and Tyr7A (or Tyr171A for short periods),
334 for approximately 95% of the simulation time. This is very interesting, since no
335 side-chain interactions have been observed in the x-ray structure of SEV9 peptide
336 (Fremont et al., 1992). Thus, overall two to three hydrogen bonds contributed to
337 peptide's binding. These results corroborate the importance of this binding pocket
338 in the peptide/MHC binding process.

339 Side chain of Glu63A (pocket B) accepted hydrogen bond from **Ala2** Nitrogen
340 atom (position P2). This interaction was conserved for 93.5% (trA) or 98.6% (trB)
341 of the simulation time, and it was well formed in the initial structure (the distance
342 between Ala2:N and Glu63A:O^{δ1} was found 2.9 Å). This finding underlines the

343 importance of the Glu63A residue, since its negatively charged side chain formed
344 two stable hydrogen bonds with the peptide's backbone amide groups. Side chain
345 of Lys66A was found in hydrogen bond state with Ala2:O atom for over 90% of the
346 simulation time. The corresponding distance between Lys66A:N ζ and Ala2:O atoms
347 in the initial structure was found 2.7 Å, indicating the existense of the hydrogen
348 bond. Moreover, side chains of Tyr7A and Tyr45A made hydrophobic contacts
349 with **Ala2**'s aliphatic side chain. The above analysis is for the **Ala2** interactions is
350 almost identical with the x-ray structure of the SEV9 peptide (Fremont et al., 1992),
351 indicating the fact the preservation of the **Ala2** residue in position P2 (binding
352 pocket B) contributed to the retaining of the same peptide/MHC interactions.

353 **Pro3** (P3) made important hydrophobic interactions with Tyr159A's side chain.
354 Average distance of their side chain centers were found 4.0 Å(0.6) or 4.2 Å(0.6)
355 during trA or trB MD trajectories respectively. For approximately 25% of the time,
356 the two side chains were found in parallel orientation forming a stacking interaction.
357 It is noted that Tyr159A's side chain donated a hydrogen bond to Ser1:O, hence
358 this MHC residue is considered to contribute significantly to peptide's binding. The
359 original hydrogen bond between Pro's backbone oxygen atom and Asn70A's side
360 chain was found to be relatively weak during trA and trB MD trajectories: 12.7 and
361 27.2% of the frames respectively satisfied the hydrogen bond criteria.

362 Central residues **Asp4** and **Thr5** did not show any significant interactions with
363 the MHC's residues. Only **Asp4**'s side chain was found hydrogen bonded to Arg62A's
364 side chain for limited period of simulation time, \approx 15%. Both residues were exposed
365 outside of the binding groove.

366 Binding pocket C plays an important role in peptide recognition by MHC H-2K^b
367 molecules (Molano et al., 1998; D. H. Fremont and E. A. Stura and M. Matsumura
368 and P. A. Peterson and I. A. Wilson, 1995; Huard et al., 1997). Peptide's residue
369 **Arg6** side chain at position P6, was found to form a strong hydrogen bond with
370 Glu24A side chain. Actually, these side chains remained hydrogen bonded the entire

371 time time in both trA and trB MD trajectories. On the other side, there was no
372 backbone interaction with the MHC molecule. However, the ability of the MHC
373 molecule to bind different peptide sequences, since the original peptide has Tyr in
374 this position (Apostolopoulos et al., 2002), which is a canonical residue at this posi-
375 tion for MHC binding. Tyr6 (SEV9 peptide) to Arg6 (MUC1-9 peptide) mutation
376 led to some loss of hydrophobic interactions between peptide and MHC molecule, a
377 fact that might explain the reduced binding affinity of the MUC1-9 peptide, relative
378 to SEV9 peptide. However, the **Arg6** remained inside the canonical C-pocket, unlike
379 the **Arg6** residue in YEA9 peptide (SRDNSRIPM) which utilized the non-canonical
380 E binding pocket (Apostolopoulos et al., 2002).

381 Residue **Pro7**, at peptide's P7 position, had a weak backbone hydrogen bond
382 with Tyr117A's side chain. Occurrence was found 28% in trA and only 7% in trB
383 trajectories respectively. Given the fact that in crystal structures of peptides bound
384 in the H-2K^b molecule, no such hydrogen bond exist (Table 2), the result is not so
385 suprising. However, significant hydrophobic interactions with Trp147A and Trp133A
386 side chains were found to contribute in peptide/MHC interactions. For example, side
387 chain distances between **Pro7** and Trp147A varied between 3 and 5 Å and averaged
388 at 3.6 Å (0.2). To a lesser degree, Leu156A and Tyr116A also made hydrophobic
389 contacts with side the chain of **Pro7**.

390 Position P8 was occupied by **Ala8**. The backbone carbonyl group of this residue
391 was found to be in hydrogen bond state with Trp147A's side chain. This is a well
392 expected interaction, as it has been found in the crystal structure of the original
393 peptide. A relatively weak hydrogen bond was also formed for part of trA trajec-
394 tory, between Ala8:N and Glu152A:Oε2. The corresponding distance in the initial
395 structure was found to be 5.8 Å.

396 Finally, residue **Pro9** at position P9 (binding pocket F). The C-terminal car-
397 boxyl group was found to form two hydrogen bonds (Table 2) with Thr143A and
398 Lys146A side chains, for almost all of the simulation time, in both trA and trB tra-

400 jecoties. The same interactions were also present in the x-ray structure that served as
401 initial point for these calculations. However, the lack of amide hydrogen in proline's
402 structure resulted to the abolishment of a backbone hydrogen bond between peptide
403 and the MHC molecule. Thus, the Leu to Pro (SEV9 to MUC1-9 peptide) mutation
404 resulted in a small shift of the position of this residue. These subtle changes in
405 peptide's conformation have been shown (Hoare et al., 2008) to affect drastically
406 the MHC recognition and might explain to some extent the reduced affinity of the
407 MUC1-9 peptide when bound to class I H-2K^b. **Pro9**'s side chain also made hy-
408 drophobic contacts with Val76A, Leu81A and Trp147A side chains. For at least 90%
409 of the simulation time, a pair of side chain heavy atoms from these residues were in
410 close contact (distance less than 4.5 Å) with a side chain heavy atom from **Pro9**.
411 These hydrophobic interactions further stabilized the peptide/MHC interactions,
412 and along with the hydrogen bonds strengthen the anchoring role of **Pro9**.

412 Overall, as it can be seen from Figure 6, there were approximately 12 hydrogen
413 bonds between the peptide and the MHC molecule, during both MD trajectories.
414 This number approximates very well the number of the reported (Fremont et al.,
415 1992) hydrogen bonds (11) between the peptide SEV9 and the MHC molecule.

416 3.4 Buried Surface Area

417 Buried surface area (BSA) is a good indicator of the binding of a ligand into a
418 protein (Olsson et al., 2008). Figure 7 shows the time evolution of BSA between
419 the peptide and the MHC molecule. BSA fluctuated between 666.9 and 1005.6 Å²
420 and averaged at 848.7(47.5) Å² in the trA trajectory. In the trB case, BSA values
421 were found between 656.7 and 999.6 Å² with mean value of 824.9(52.9) Å². As it is
422 can be drawn from the graphical representation of BSA time evolution, and from
423 basic statistical analysis, both trajectories showed similar profiles for the calculated
424 BSA of peptide/MHC interface. The difference of approximately 25 Å² (3%) in the
425 mean values is very small and could be considered to be within expected error. In

426 a recent experimental re-investigation of BSA of protein x-ray structures (Novotny
427 et al., 2007) it was suggested that differences from 50 to 100 \AA^2 in BSA values
428 were expected as a measurement error rather than actual difference in BSA. These
429 findings corroborate our statement that the peptide/MHC complex was stable and
430 that the fluctuations in BSA time series are normal.

431 The BSA value in the x-ray structure of the SEV9 peptide was 1076 \AA^2 , while
432 the BSA value in the MUC1-9/MHC complex after restrained energy minimization
433 was found to be 937.5 \AA^2 . The loss of approximately 140 \AA^2 can be attributed to
434 minor conformational changes that occurred during MD run in order for the mutated
435 peptide to adapt to the binding groove of the MHC molecule. Considered, however,
436 that trajectories were obtained in 310 K, thus the spontaneous thermal moving of
437 the atoms resulted in somewhat reduced BSA values.

438 Thus, the difference of more than 140 \AA^2 in the BSA of the peptide/MHC in-
439 terface, in the SEV9 and MUC1-9 cases, is another indication of the lower binding
440 affinity that the MUC1-9 has to the H-2K^b molecule, relatively to the SEV9 peptide.

441 **4 Concluding remarks**

442 Homology modeling and molecular dynamics simulations have been used to assess
443 the structure of the SAPDTRPAP/H-2K^b complex. Results presented here indicate
444 that a stable complex is formed, based on the analysis of two MD trajectories.

445 MHC binding pockets A and F interacted closely with the N- and C-terminus
446 of the peptide which played an important role in stabilizing the complex. The
447 Buried Surface Area of the peptide/H-2K^b interface remained constant during the
448 simulation indicating the stability of the complex and its similarity to the initial
449 peptide/MHC complex.

450 Replacement of Leu with Pro at P9 position did not affect significantly the
451 MHC's binding of the peptide. The C-terminal carboxyl group was found to form

452 stable hydrogen bonds with the MHC molecule, and the non-polar side chain of Pro
453 residue made a number of close contacts with hydrophobic residues of the MHC's
454 F binding pocket. However, the peptide showed relatively increased mobility in the
455 C-terminal region, that may affect the strength of the MHC binding.

456 A main difference between MUC1-9's simulated structure and SEV9's x-ray
457 structure was the ϕ angle of **Thr5**. A significant transition from $+74^\circ$ to $\approx -150^\circ$
458 occurred. Since it is well known that backbone conformation plays a very important
459 role in peptide/MHC recognition (Barinaga, 1992), it is expected that this confor-
460 mational transition would alter the MHC's binding affinity for the peptide, most
461 possibly downwards. Moreover, MHC H-2K^b molecules prefer hydrophobic residues
462 at position P6 (for nonamer peptides), even though MUC1-9 has Arg in this place.

463 This has resulted in a notable alteration of the backbone conformation of the
464 central part of peptide and the enhancement of the exposure of the Asp4-Thr5 region
465 outside of the MHC's binding groove. For a considerable amount of simulation time
466 this bulged region adopted a β -turn conformation, however without the presence
467 of the characteristic hydrogen bond. This had not been noted in previous mod-
468 eling studies (Apostolopoulos et al., 1998) and provides a new framework for the
469 peptide/MHC interactions.

470 Inclusion of explicit water molecules in the current study helped a lot to clarify
471 the role of the solvent in peptide/MHC interactions. Water mediated hydrogen
472 bonds were found only sparingly and although existed, a clear contribution to the binding
473 process can not be attributed to this kind of interaction.

474 Leu to Pro mutation at position P9 resulted in slight movement of this residue
475 within the F binding pocket. However, this fact, along with the loss of a hydrogen
476 bond interaction of the Leu amide hydrogen might be enough reason for observing
477 the reduced affinity of the MUC1-9 peptide to H-2K^b binding.

478 All of the above observations reflected well in the reduction of the BSA between
479 the peptide and the MHC molecule, where a loss of 140 \AA^2 has been measured.

480 Finally, it seems that while the MUC1-9 peptide forms stable complex with the H-
481 2K^b molecule, it is clear that certain structural reorganization occurred and resulted
482 in reduced binding affinity.

483 Acknowledgements

484 NAMD parallel execution have been performed at the Research Center of Scientific
485 Simulations (RCSS) of the University of Ioannina. The open source community is
486 gratefully acknowledged for providing all the necessary tools (Linux, NAMD, GNU,
487 etc) that made this work possible.

488 References

- 489 Agostinelli, C., 2009. Circular Statistics with R.
490 URL <http://cran.r-project.org/web/packages/circular/index.html>
- 491 Aksimentiev, A., Brunner, R., Cohen, J., Comer, J., Cruz-Chu, E., Hardy, D., Rajan, A.,
492 Shih, A., Sigalov, G., Yin, Y., Schulten, K., 2008. Computer modeling in biotechnology:
493 a partner in development. *Methods Mol Biol* 474, 181–234.
- 494 Apostolopoulos, V., G Chelvanayagam, P. X. X., McKenzie, I. F., 1998. Anti-MUC1 anti-
495 bodies react directly with MUC1 peptides presented by class I H2 and HLA molecules.
496 *J Immunol* 161, 767–775.
- 497 Apostolopoulos, V., Haurum, J. S., McKenzie, I. F., 1997. MUC1 peptide epitopes asso-
498 ciated with five different H-2 class I molecules. *Eur J Immunol* 27, 2579–2587.
- 499 Apostolopoulos, V., Lazoura, E., 2004. Noncanonical peptides in complex with MHC class
500 I. *Expert Rev Vaccines* 3, 151–162.
- 501 Apostolopoulos, V., Yu, M., Corper, A. L., Li, W., McKenzie, I. F. C., Teyton, L., Wilson,
502 I. A., Plebanski, M., 2002. Crystal structure of a non-canonical high affinity peptide
503 complexed with MHC class I: a novel use of alternative anchors. *J Mol Biol* 318, 1307–
504 1316.
- 505 Baker, N. A., Sept, D., Joseph, S., Holst, M., McCammon, J. A., 2001. Electrostatics of
506 nanosystems: application to microtubules and the ribosome. *Proc Natl Acad USA* 98,
507 10037–10041.
- 508 Barinaga, M., 1992. Getting some "backbone": how MHC binds peptides. *Science* 257,
509 880–881.
- 510 Berman, H. M., Battistuz, T., Bhat, T. N., Bluhm, W. F., Bourne, P. E., Burkhardt,
511 K., Feng, Z., Gilliland, G. L., Iype, L., Jain, S., Fagan, P., Marvin, J., Padilla, D.,

512 Ravichandran, V., Schneider, B., Thanki, N., Weissig, H., Westbrook, J. D., Zardecki,
513 C., 2002. The Protein Data Bank. *Acta Crystall Sec D: Biol Crystall* 58, 899–907.

514 Bjorkman, P. J., Saper, M. A., Samraoui, B., Strominger, W. S., Wiley, D. C., 1987.
515 Structure of the human class I histocompatibility antigen, HLA-A2. *Nature* 329, 506–
516 512.

517 Buck, M., Bouguet-Bonnet, S., Pastor, R., MacKerell, A., 2006. Importance of the CMAP
518 correction to the CHARMM22 protein force field: dynamics of hen lysozyme. *Biophys-*
519 *ical Journal* 90, 36–38.

520 Burchell, J., Taylor-Papadimitriou, J., Boshell, M., Gendler, S., Duhig, T., 1989. A short
521 sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains
522 immunodominant epitopes. *Int J Cancer* 44, 691–696.

523 Chelvanayagam, G., Jakobsen, B., Gao, X., Easteal, S., 1996. Structural comparison of
524 major histocompatibility complex class I molecules and homology modelling of five
525 distinct human leukocyte antigen-A alleles. *Protein Engineering* 9, 1151–1164.

526 D. H. Fremont and E. A. Stura and M. Matsumura and P. A. Peterson and I. A. Wilson,
527 1995. Crystal structure of an H-2K^b-ovalbumin peptide complex reveals the interplay
528 of primary and secondary anchor positions in the major histocompatibility complex
529 binding groove. *Proc Natl Acad Sci USA* 92, 2479–2483.

530 Darden, T., York, D., Pedersen, L., 1993. Particle mesh ewald: An $N \log(N)$ method for
531 ewald sums in large systems. *J Chem Phys* 98, 10089–1092.

532 Dolinsky, T. J., Nielsen, J. E., McCammon, J. A., Baker, N. A., 2004. PDB2PQR: an
533 automated pipeline for the setup of Poisson–Boltzmann electrostatics calculations. *Nucl*
534 *Acids Res* 32, W665–W667.

535 Feller, S. E., Zhang, Y., Pastor, R. W., Brooks, B. R., 1995. Constant pressure molecular
536 dynamics simulation: The Langevin piston method. *J Chem Phys B* 103, 4613–4621.

537 Fremont, D. H., Matsumura, M., Stura, E. A., Peterson, P. A., Wilson, I. A., 1992. Crystal
538 structures of two viral peptides in complex with murine MHC class I H-2K^b. *Science*
539 257, 919–927.

540 Frishman, D., Argos, P., 1995. Knowledge-based protein secondary structure assignment.
541 *Proteins: Structure, Function and Genetics* 23, 566–579.

542 Galeazzi, R., 2009. Molecular Dynamics as a Tool in Rational Drug Design: Current Status
543 and Some Major Applications. *Current Computer-Aided Drug Design* 5, 225–240.

544 Gendler, S., Taylor-Papadimitriou, J., Duhig, T., Rothbard, J., Burchell, J., 1988. A highly
545 immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas
546 is made up of tandem repeats. *J Biol Chem* 263, 12820–12823.

547 Glykos, N. M., 2006. Software news and updates. Carma: a molecular dynamics analysis
548 program. *J Comput Chem* 27, 1765–8.

549 Hansson, T., Oostenbrink, C., van Gunsteren, W. F., 2002. Molecular dynamics simula-
550 tions. *Curr Opin Struct Biol* 12, 190–196.

- 551 Hoare, H., Sullivan, L., Clements, C., Ely, L., Beddoe, T., Henderson, K., Lin, J., Reid,
552 H., Brooks, A., Rossjohn, J., 2008. Subtle Changes in Peptide Conformation Profoundly
553 Affect Recognition of the Non-Classical MHC Class I Molecule HLA-E by the CD94–
554 NKG2 Natural Killer Cell Receptors. *J Mol Biol* 377, 1297–1303.
- 555 Huard, R., Dyall, R., Nikolić-Žugić, J., 1997. The critical role of a solvent-exposed residue
556 of an MHC class I-restricted peptide in MHC-peptide binding. *International Immunol-*
557 *ogy* 9, 1701–1707.
- 558 Humphrey, W., Dalke, A., Schulten, K., 1996. VMD: Visual Molecular Dynamics. *J Mol*
559 *Graph* 14, 33–38.
- 560 Hutchinson, E. G., Thornton, J. M., 1994. A revised set of potentials for beta-turn forma-
561 tion in proteins. *Protein Sci* 3, 2207–22016.
- 562 Karplus, M., 2003. Molecular dynamics of biological macromolecules: a brief history and
563 perspective. *Biopolymers* 68, 350–358.
- 564 Knapp, B., Omasits, U., Frantal, S., Schreiner, W., 2009. A critical cross-validation of
565 high throughput structural binding prediction methods for pMHC. *J Comp Aid Mol*
566 *Des* 23, 301–307.
- 567 Kollman, P., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T.,
568 Duan, Y., Wang, W., et al., 2000. Calculating structures and free energies of complex
569 molecules: combining molecular mechanics and continuum models. *Acc Chem Res* 33,
570 889–897.
- 571 MacKerell, A. D., Feig, M., Brooks, C. L., 2004. Extending the treatment of backbone
572 energetics in protein force fields: Limitations of gas-phase quantum mechanics in re-
573 producing protein conformational distributions in molecular dynamics simulations. *J*
574 *Comput Chem* 25, 1400–1415.
- 575 Mackerell, A. D., Feig, M., Brooks, C. L., 2004. Improved treatment of the protein back-
576 bone in empirical force fields. *J Am Chem Soc* 126, 698–699.
- 577 Mallik, B., Morikis, D., 2006. Applications of Molecular Dynamics Simulations in Im-
578 munology: A Useful Computational Method in Aiding Vaccine Design. *Curr Proteom*
579 3, 259–270.
- 580 Matsamura, M., Fremont, D. H., Peterson, P. A., Wilson, I. A., 1992. Emerging principles
581 for the recognition of peptide antigens by MHC class I molecules. *Science* 257, 927–934.
- 582 Meijers, R., Lai, C. C., Yang, Y., Liu, J. H., Zhong, W., Wang, J. H., Reinherz, E. L.,
583 2005. Crystal Structures of Murine MHC Class I H-2 D^b and K^b Molecules in Complex
584 with CTL Epitopes from influenza A Virus: Implications for TCR Repertoire Selection
585 and Immunodominance. *J Mol Biol* 345, 1099–1110.
- 586 Molano, A., Erdjument-Bromage, H., Fremont, D., Messaoudi, I., Tempst, P., Nikolic-
587 Zugić, J., 1998. Peptide selection by an MHC H-2Kb class I molecule devoid of the
588 central anchor ("C") pocket. *The Journal of Immunology* 160, 2815–2823.
- 589 Morikis, D., Lambris, J. D., 2004. Physical methods for structure, dynamics and binding
590 in immunological research. *Trends Immunol* 25, 700–707.

- 591 Novotny, M., Seibert, M., Kleywegt, G. J., 2007. On the precision of calculated solvent-
592 accessible surface areas. *Acta Crystallographica Section D* 63, 270–274.
- 593 Olsson, T. S. G., Williams, M. A., Pitt, W. R., Ladbury, J. E., 2008. The thermodynamics
594 of protein–ligand interaction and solvation: Insights for ligand design. *J Mol Biol* 384,
595 1002–1007.
- 596 Omasits, U., Knapp, B., Neumann, M., Steinhauser, O., Stockinger, H., Kobler, R.,
597 Schreiner, W., 2008. Analysis of key parameters for molecular dynamics of pMHC
598 molecules. *Molecular Simulation* 34, 781–793.
- 599 Petrone, P., Garcia, A., 2004. MHC–peptide binding is assisted by bound water molecules.
600 *J Mol Biol* 338, 419–435.
- 601 Price, M., F., H., O’Sullivan, C., Baldwin, R., Edwards, P., Tendler, S., 1991. Immunolog-
602 ical and structural features of the protein core of human polymorphic epithelial mucin.
603 *Mol Immunology* 27, 795–802.
- 604 Raghavan, M., Del Cid, N., Rizvi, S., Peters, L., 2008. MHC class I assembly: out and
605 about. *Trends in Immunology* 29, 436–443.
- 606 Sadiq, S. K., Mazzeo, M. D., Zasada, S. J., Manos, S., Stoica, I., Gale, C. V., Watson,
607 S. J., Kellam, P., Brew, S., Coveney, P. V., 2008. Patient-specific simulation as a basis
608 for clinical decision-making. *Phil Trans R Society A* 366, 3199–3219.
- 609 Saper, M. A., Bjorkman, P. J., Wiley, D. C., 1991. Refined Structure of the Human
610 Histocompatibility Antigen HLA-A2 at 2.6 Å Resolution. *J Mol Biol* 219, 277–319.
- 611 Stavrakoudis, A., 2008. Molecular dynamics simulations of an apolipoprotein derived peptide.
612 *Chem Phys Lett* 461, 294–299.
- 613 Stavrakoudis, A., 2009a. A disulfide linked model of the complement protein C8 γ com-
614 plexed with C8 α indel peptide. *J Mol Model* 15, 165–171.
- 615 Stavrakoudis, A., 2009b. Computational modeling and molecular dynamics simulations
616 of a cyclic peptide mimotope of the CD52 antigen complexed with CAMPATH-1H
617 antibody. *Mol Sim* 36, 127–137.
- 618 Stavrakoudis, A., 2010. Conformational Flexibility in Designing Peptides for Immunology:
619 The Molecular Dynamics Approach. *Curr Comput-Aided Drug Design* 6, in press.
620 URL <http://www.ncbi.nlm.nih.gov/pubmed/20412039>
- 621 Tang, C.-K., Katsara, M., Apostolopoulos, V., 2008a. Strategies used for muc1 im-
622 munotherapy: human clinical studies. *Expert Rev Vaccines* 7, 963–975.
- 623 Tang, C.-K., Katsara, M., Apostolopoulos, V., 2008b. Strategies used for muc1 im-
624 munotherapy: preclinical studies. *Expert Rev Vaccines* 7, 951–962.
- 625 Tantar, A. A., Conilleau, S., Parent, B., Melab, N., Brillet, L., Roy, S., Talbi, E.-L.,
626 Horvath, D., 2008. Docking and Biomolecular Simulations on Computer Grids: Status
627 and Trends. *Cur Comput Aid Drug Des* 4, 235–249.

- 628 Tatsis, V. A., Tsoulos, I. G., Stavrakoudis, A., 2009. Molecular Dynamics Simulations of
629 the TSSPSAD Peptide Antigen in Free and Bound with CAMPATH-1H Fab Antibody
630 States: The Importance of the β -Turn Conformation. *Int J Pept Res Ther* 15, 1–9.
- 631 Tsoulos, I. G., Stavrakoudis, A., 2009. Eucb: a C++ program for trajectory analysis,
632 <http://stavrakoudis.econ.uoi.gr/eucb>.
- 633 van Gunsteren, W. F., Dolenc, J., Mark, A. E., 2008. Molecular simulation as an aid to
634 experimentalists. *Curr Opin Struct Biol* 18, 149–53.
- 635 Wan, S., Coveney, P., Flower, D., 2005. Peptide recognition by the T cell receptor: com-
636 parison of binding free energies from thermodynamic integration, Poisson–Boltzmann
637 and linear interaction energy approximations. *Philosophical Transactions of the Royal*
638 *Society A: Mathematical, Physical and Engineering Sciences* 363, 2037.
- 639 Wan, S., Flower, D. R., Coveney, P. V., 2008. Toward an atomistic understanding of the
640 immune synapse: large-scale molecular dynamics simulation of a membrane-embedded
641 TCR-pMHC-CD4 complex. *Mol Immunol* 45, 1221–1230.
- 642 Word, J. M., Lovell, S. C., Richardson, J. S., Richardson, D. C., 1999. Asparagine and
643 glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation.
644 *J Mol Biol* 285, 1735–1747.
- 645 Xing, P.-X., Prenzoska, J., McKenzie, I., 1992. Epitope mapping of anti-breast and anti-
646 ovarian mucin monoclonal antibodies. *Mol. Immunology* 29, 641–650.
- 647 Xing, P.-X., Reynolds, K., Pietersz, G., McKenzie, I., 1991. Effect of variations in peptide
648 sequence on anti-human milk fat globule membrane antibody reactions. *Immunology*
649 72, 304–311.
- 650 Yonetani, Y., 2006. Liquid water simulation: a critical examination of cutoff length. *J*
651 *Chem Phys* 124, 204501.
- 652 Zavala-Ruiz, Z., Strug, I., Walker, B. D., Norris, P. J., Stern, L. J., 2004. A hairpin turn
653 in a II MHC-bound peptide orients outside the binding groove for T cell recognition.
654 *Proc Nat Acad Sci USA* 101, 13279–13284.
- 655 Zhang, C., Anderson, A., DeLisi, C., 1998. Structural principles that govern the peptide-
656 binding motifs of class I MHC molecules. *J Mol Biol* 281, 929–947.

657 Tables

658 **Table 1** Backbone dihedral angles in the region Asp4-Thr5 of the MUC1-9 peptide,
659 where a β -turn was found in the MUC1-9 peptide. Corresponding region of the
660 SEV9 peptide is Gly4-Asn5. Column PDB lists the corresponding values from the
661 crystal structure of the SEV9 peptide, with the residues Gly and Asn at positions
662 4 and 5 respectively. Averages values (and variances in parentheses) is given from
663 trajectories tr0, trA and trB.

Dihedral	PDB	tr0	trA	trB
ϕ_4	-119.9	-138.3 (4.9)	-67.8 (1.1)	-69.4 (1.2)
ψ_4	153.2	-173.3 (3.6)	-34.8 (1.3)	-35.4 (1.2)
ϕ_5	74.4	58.8 (0.9)	-151.3 (2.1)	-151.4 (2.2)
ψ_5	48.2	49.2 (1.1)	161.7 (3.5)	160.0 (3.9)

664 **Table 2** Hydrogen bond interactions between the SEV9 and MUC1-9 peptides and
665 the H-2K^b molecule. Percentage of frames is given, from trajectories tr0, trA and
666 trB, that met the geometrical criteria for hydrogen bond interaction. Distance
667 between donor-acceptor atoms are taken from the initial structure (PDB column).

Donor	Acceptor	PDB (Å)	tr0 (%)	trA (%)	trB (%)
Phe _{1P} :N	Tyr _{59A} :O ^η	4.13	32.4		
Phe _{1P} :N	Glu _{63A} :O ^{ε_{1,2}}	4.61	95.6		
Ser _{1P} :N	Glu _{63A} :O ^{ε_{1,2}}	5.83		93.2	94.1
Tyr _{159A} :O ^η	Ser _{1P} :O	2.67	59.6	91.4	94.8
Tyr _{59A} :O ^η	Ser _{1P} :O ^γ	5.77		77.7	81.9
Ser _{1P} :O ^γ	Tyr _{7A} :O ^η	5.82		93.2	97.9
Ser _{1P} :O ^γ	Tyr _{171A} :O ^η	5.00			20.6
Ala _{2P} :N	Glu _{63A} :O ^{ε_{1,2}}	2.90	90.1	93.5	98.6
Lys _{66A} :N ^ζ	Ala _{2P} :O	2.74	76.6	97.3	90.0
Asn _{70A} :N ^δ	Pro _{3P} :O	3.63	63.4	12.7	27.2
Arg _{62A} :N ^{η₂}	Asp _{4P} :O ^{δ_{1,2}}	6.78		19.0	
Arg _{6P} :N ^{η_{1,2}}	Glu _{24A} :O ^{ε_{1,2}}	5.21		92.4	97.2
Tyr _{116A} :O ^η	Pro _{7P} :O	4.11		28.2	7.2
Ala _{8P} :N	Glu ₁₅₂ :O ^{ε_{1,2}}	5.87		38.5	5.5
Trp _{147A} :N ^ε	Ala _{8P} :O	2.86	11.7	70.4	98.5
Leu _{9P} :N	Asp _{77A} :O ^{δ_{1,2}}	3.02	82.4		
Lys _{146A} :N ^ζ	Leu _{9P} :O ^{τ₂}	3.00	95.2		
Tyr _{84A} :O ^η	Leu _{9P} :O ^{τ₂}	2.84	39.3		
Thr _{143A} :O ^γ	Pro _{9P} :O ^{τ_{1,2}}	2.68		94.1	92.7
Lys _{146A} :N ^ζ	Pro _{9P} :O ^{τ_{1,2}}	3.00		98.6	98.7

668 **Figures**




Figure 1: Root mean square fluctuation (left column) of C^α atoms and root mean square deviation (right column) time series of backbone atoms (N, C^α , C') of the pMHC complex after fitting the corresponding atom positions from MD trajectory to initial (X-ray) coordinates. Results from different trajectories (tr0, trA and trB) are indicated with different line colors. A) RMSF of MHC chain A, B) RMSF of MHC chain B, C) RMSF of MHC chain P (peptide), D) RMSD of MHC chain A, E) RMSD of MHC chain B and F) RMSD of MHC chain P (peptide).




Figure 2: Ramachandran plot of backbone dihedral angles of the peptide. Horizontal axis is for ϕ and vertical axis is for ψ angle respectively. The plots represent propability density maps, z-axis is the percentage of frames found within 10° dihedral angle bin. The adjacent colour bar is used to identify regions of low (grey) versus high (blue) populations.




Figure 3: A) Ribbon representation of five selective structures of the MUC1-9/H-2K^b complex (one frame every 2 ns) from trA trajectory, B) Ribbon representation of five selective structures of the MUC1-9/H-2K^b complex (one frame every 2 ns) from trB trajectory, C) Stick representation of the peptide bound in the MHC groove from trA trajectory, D) Stick representation of the peptide bound in the MHC groove from trB trajectory, E) Important hydrogen bond interactions between the peptide and MHC molecule in the trA trajectory and F) Important hydrogen bond interactions between the peptide and MHC molecule in the trB trajectory. Hydrogens were omitted from stick representations. Structures have been fitted to the first frame using the backbone atoms.




Figure 4: Peptide's (sticks) orientation in MHC (ribbons) binding groove in trA (A) and trB (B) trajectories. Exposure to the solvent of the region **Asp4-Thr5**, while **Arg6** side chain orientates towards the beta-sheet floor, in the interior of the binding groove of pocket C, in trA (C) and trB (D) trajectories.




Figure 5: A) and B) Backbone overlay of the Pro3-Arg6 region of the peptide from the trA and trB trajectories respectively. This fragment has been found in β -turn conformation for considerable amount of time. C) Backbone superimposition of SEV9 peptide (green) from the X-ray structure with representative structures from trA (cyan) and trB (orange) trajectories. The differentiation of backbone conformation at fragment **Asp4-Thr5** is well seen. Side chains of residues 2, 3, 6 and 7 share common orientation towards the MHC binding groove. Interestingly, conformations of residues at positions 1 and 9 deviate from the original structure.




Figure 6: A) Total number of hydrogen bonds between the peptide and the MHC molecule, as evolved over simulation time. Data were averaged every 10 ps. B) Total number of water mediated hydrogen bonds between the peptide and MHC molecule, as evolved over simulation time. Data were taken every 10 ps.




Figure 7: Time series of apolar buried surface area (BSA) between the peptide and the MHC molecule in tr0, trA and trB trajectories.